Obeticholic Acid—A Pharmacological and Clinical Review

Citicoline: pharmacological and clinical review, 2010 update

Introduction S1 Pharmacological actions S2 Traumatic lesions and experimental cerebral oedema S2 Cerebral hypoxia and ischaemia S5 Synaptic transmission and neurotransmitter levels S13 Learning performance, memory and brain ageing S17 Experimental withdrawal syndrome and intoxications S19 Toxicity S20 Acute toxicity S20 Subacute toxicity S20 Chronic toxicity S20 Teratogenicity S20 Pharmacokinet...

Citicoline: pharmacological and clinical review, 2016 update.

This review is based on the previous one published in 2010 -Secades JJ. Citicoline: pharmacological and clinical review, 2010 update. Rev Neurol 2011; 52 (Suppl 2): S1-62-, incorporating 183 new references, having all the information available to facilitate the access to the information in one document. This review is focused on the main indications of the drug, as acute stroke and its sequelae...

Citicoline: pharmacological and clinical review, 2006 update.

Cytidine 5'-diphosphocholine, CDP-choline, or citicoline is an essential intermediate in the biosynthetic pathway of structural phospholipids in cell membranes, particularly phosphatidylcholine. Following administration by both the oral and parenteral routes, citicoline releases its two main components, cytidine and choline. Absorption by the oral route is virtually complete, and bioavailabilit...

Pharmacological Properties of Resveratrol. A Pre-Clinical and Clinical Review

Resvertrol (Resv) is an extensively studied molecule – as of 2015 PubMed held more than 7100 publications on the subject. The First International Resveratrol Conference in 2010 found insufficient evidence to justify recommending chronic administration of Resv in humans, a finding in stark contrast with the claims of its therapeutic effects often made by the media, based on its supposed role in ...

Andrographis paniculata: a review of pharmacological activities and clinical effects.